atopic dermatitis

Apogee claims IL-13 antibody sets new eczema treatment standard

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main goal of a phase 2 trial.

James Waldron Jul 7, 2025 8:29am

bee flying away bee nectar flower pollen plant lilac

Nektar stock doubles as phase 2b eczema trial hits endpoints

Jun 24, 2025 9:20am

An arrow incrementally going up stairs before pointing straight up Blue background

Leo's eczema prospect hits primary endpoint in phase 2b

May 9, 2025 7:30am

rocket launch satellite space fly blast off

Amgen ignites Rocket program with wins in phase 3 eczema trials

Mar 10, 2025 5:48am

Q32 Bio sticks with bempikibart but lets go of staff

Feb 11, 2025 4:47am

Ikena, after tough year of layoffs, merges with Inmagene

Dec 23, 2024 10:00am